GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues, principally to the …

GD2 ganglioside is a sialic acid-containing glycosphingolipid, whose structure is characterized by two distinct portions with different physicochemical properties. It is composed of a hydrophobic ceramide …

Jun 28, 2025 · GD2 is a type of molecule called a disialoganglioside, a complex structure of lipids and sugars. These molecules embed themselves in the outer membrane of cells, where they are involved …

Feb 7, 2025 · While various glycosphingolipids were identified as cancer-associated carbohydrate antigens to be used as tumor markers, disialylated gangliosides such as GD3 and GD2 have …

Aug 21, 2025 · This work provides an overview of GD2 biology in terms of synthesis pathway and expression, as well as a critical review of the GD2-based targeted therapies for pediatric CNS tumors.

Mar 15, 2024 · Structurally, GD2 is a glycosphingolipid that is stably expressed on the surface of tumor cells, making it a suitable candidate for targeting by antibodies or chimeric antigen receptors.

Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside …

Jan 2, 2025 · Researchers at Stanford University, who led the study, designed the experimental CAR T-cell therapy to target a molecule called GD2 that is produced in large amounts by H3K27M-mutant …

Apr 5, 2023 · In an academic, phase 1–2 clinical trial, we enrolled patients (1 to 25 years of age) with relapsed or refractory, high-risk neuroblastoma in order to test autologous, third-generation GD2 …

Structurally, GD2 is a glycosphingolipid that is stably expressed on the surface of tumor cells, making it a suitable candidate for targeting by antibodies or chimeric antigen receptors.